Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Although cardiovascular disease is a major cause of morbidity and death in Chronic Kidney Disease, few therapies have proved effective in moderating increased cardiovascular disease risk or the rate of renal decline in CKD.

Jointly funded by the NIHR School for Primary Care Research and the NIHR Health Technology Assessment Programme, the Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial is the largest primary care based chronic kidney disease trial conducted to date.

Led by the Primary Care CTU at the University of Oxford and with seven recruitment centres across the country, BARACK D aims to determine whether an established cardiovascular medication, spironolactone, can reduce cardiovascular risk and the decline in renal function. The trial aims to recruit 2910 participants through 300 GP practices across the country.
At the end of September the trial had reached a milestone by recruiting 430 participants.